Enzymlogic, the world leader in the kinetic profiling of compounds to facilitate drug discovery, celebrates its 10th anniversary with a legacy of innovation, collaboration, and scientific advancement. Since its foundation a decade ago, the company has stood out for its commitment to developing revolutionary technologies aimed at transforming the landscape of the pharmaceutical industry.
With the mission to revolutionize the way drugs are discovered, the company has pioneered two cutting-edge technological platforms: KINETICfinder® and COVALfinder®. These innovative tools have enabled routine kinetic evaluation of drugs during the early stages of drug discovery, empowering drug hunters to expedite discovery decision-making: pinpointing the most promising drugs and discarding underperforming ones.
Last year, Enzymlogic significantly expanded its capabilities and laboratory, investing in state-of-the-art infrastructure and attracting exceptional scientific talent. This expansion has further strengthened its ability to conduct pioneering research and facilitate disruptive breakthroughs in drug discovery.
Over these ten years, the company has forged strong collaborations with academia, small biotech firms and big pharmaceutical companies worldwide. We are immensely proud to have contributed to advancing the discovery of new drugs and enhancing patients’ health.
The exponential growth has been reflected not only in technological advancements but also in the human team. Since its inception, the company’s team has experienced notable growth, comprising highly skilled, creative, and dedicated professionals who have propelled the company towards new horizons.
As we celebrate this first decade of achievements, Enzymlogic reaffirms its commitment to scientific excellence and continuous innovation in the field of drug discovery. With eyes set on the future, it is poised to maintain a highly engaged relationship with its clients and expand its service portfolio to anticipate and meet their evolving needs.
About Enzymlogic
Enzymlogic is a world leader in kinetic profiling of compounds to facilitate drug discovery. As experts in the generation and interpretation of kinetic data, we pride ourselves on a proven track record of successful partnerships with worldwide organizations of all sizes, supporting them on a routine basis during the early phases of drug discovery.
We focus on the Hit to Lead (H2L) and Lead Optimization (LO) stages of drug discovery where our optimized kinetic profiling assays identify compounds with therapeutic potential that merit further progression into clinical trials.